Rigor Reviewed

Rigor-Reviewed Manuscript

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Name: Αlpha¹ Rigor Record — IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Item: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Rating: 96
Author: Αlpha¹

Chertow GM, Chang AM, Felker GM, Heise M, Velkoska E, Fellström B, Charytan DM, Clementi R, Gibson CM, Goodman SG, Jardine M, Levin A, Lokhnygina Y, Mears J, Mehran R, Stenvinkel P, Wang AY, Wheeler DC, Zoccali C, Ridker PM, Mahaffey KW, Tricoci P, Wolf M

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Data look implausibly cleanAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 2b randomized controlled trial with strong methodology, clear ethics approvals, and transparent reporting. The main weakness is the vague data availability statement, which lacks a concrete access mechanism or timeframe. Minor reporting inconsistencies (P < 0.001 vs P < 0.0001) and a typo in the abstract should be corrected.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence in study type (interventional). The statistics verification component could not recompute any tests because only threshold p-values were reported; this does not confirm statistical correctness. The citation check found no retracted or unresolved references.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites extensive prior work (CANTOS, lipid-lowering trials, Mendelian randomization) and acknowledges limitations of prior research (e.g., exclusion of ESKD patients from trials). The rationale linking IL-6 to cardiovascular risk in dialysis patients is clearly articulated, and the hypothesis follows logically. Limitations of prior research are addressed by designing a trial specifically in this population.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on IL-6 pathway, inflammation in ESKD, and prior trials, and provides a logical rationale for the study hypothesis.

Evidence

direct quote[Main, paragraph 1-2]

“Evidence suggests a causal role of activation of the interleukin-6 (IL-6) pathway”